6.35

5.93% -0.40

Pre-market: 6.50 0.15 +2.36%

Regenxbio Inc (RGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Regenxbio Inc stock is traded at $6.35, with a volume of 1.57M. It is down -5.93% in the last 24 hours and down -32.01% over the past month. Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Previous Close:

$6.75

Open:

$6.73

24h Volume:

1.57M

Relative Volume:

1.40

Market Cap:

$328.28M

Revenue:

$170.44M

Net Income/Loss:

$-193.88M

P/E Ratio:

-1.6915

EPS:

-3.7541

Net Cash Flow:

$-126.38M

1W Performance:

+11.01%

1M Performance:

-32.01%

6M Performance:

-46.19%

1Y Performance:

-35.60%

1-Day Range:

$6.305

$6.88

1-Week Range:

$5.455

$6.88

52-Week Range:

$5.455

$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Name

Regenxbio Inc

Sector

Healthcare (1106)

Industry

Biotechnology (618)

Phone

240-552-8181

Address

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Employee

371

Twitter

@REGENXBIO

Next Earnings Date

2026-05-18

Latest SEC Filings

RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RGNX Regenxbio Inc	6.35	348.96M	170.44M	-193.88M	-126.38M	-3.7541
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Feb-11-25	Downgrade	Goldman	Buy → Neutral
Feb-07-25	Resumed	Raymond James	Outperform
Nov-15-24	Resumed	Morgan Stanley	Overweight
Oct-10-24	Resumed	Raymond James	Outperform
Jun-07-24	Initiated	Goldman	Buy
Mar-11-24	Initiated	H.C. Wainwright	Buy
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-21-24	Resumed	Raymond James	Outperform
Nov-01-23	Initiated	Stifel	Buy
Jun-02-23	Initiated	Robert W. Baird	Outperform
Jun-23-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Wedbush	Neutral
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy
Dec-16-20	Initiated	UBS	Buy
Jun-25-20	Resumed	BofA/Merrill	Buy
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform
Jun-18-19	Reiterated	Chardan Capital Markets	Buy
Jun-14-19	Resumed	Raymond James	Outperform
Jun-05-19	Reiterated	Chardan Capital Markets	Buy
Feb-25-19	Upgrade	Evercore ISI	In-line → Outperform
Feb-05-19	Upgrade	Raymond James	Outperform → Strong Buy
Dec-17-18	Reiterated	Chardan Capital Markets	Buy
Nov-08-18	Reiterated	BofA/Merrill	Neutral
Aug-08-18	Reiterated	Chardan Capital Markets	Buy
Jul-23-18	Downgrade	BofA/Merrill	Buy → Neutral
Jul-10-18	Reiterated	Chardan Capital Markets	Buy
May-09-18	Reiterated	Barclays	Overweight
Apr-09-18	Reiterated	Chardan Capital Markets	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Feb-13-18	Initiated	Mizuho	Neutral
Nov-09-17	Resumed	Morgan Stanley	Overweight

View All

Regenxbio Inc Stock (RGNX) Latest News

12:08 PM

REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace

12:08 PM

May 25, 2026

RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success - MSN

May 25, 2026

May 24, 2026

Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo

May 24, 2026

REGENXBIO to push for accelerated approval of DMD gene therapy - MSN

May 24, 2026

May 20, 2026

RGNX: Rolling BLA for Duchenne gene therapy set for Q3 2024, with robust data and regulatory momentum - TradingView

May 20, 2026

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Insider Monkey

May 20, 2026

Biotech REGENXBIO lines up May investor talks in New York and online - Stock Titan

May 18, 2026

Gene therapy innovation gains momentum at REGENXBIO during ASGCTherapy event - Traders Union

May 18, 2026

Regenxbio slides after late-stage trial data for Duchenne therapy - MSN

May 18, 2026

May 17, 2026

StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate - Genetic Engineering and Biotechnology News

May 17, 2026

What's Behind Regenxbio's Recent Plunge - Kavout

May 17, 2026

REGENXBIO Inc stock (US75901B1052): gene therapy pipeline in focus after recent data update - AD HOC NEWS

May 17, 2026

May 16, 2026

REGENXBIO: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results (NASDAQ:RGNX) - Seeking Alpha

May 16, 2026

RegenXBio (RGNX) Gets a Buy from RBC Capital - The Globe and Mail

May 16, 2026

RGNX Technical Analysis & Stock Price Forecast - Intellectia AI

May 16, 2026

May 15, 2026

RGNX Maintained by B of A Securities -- Price Target Lowered to $14 - GuruFocus

May 15, 2026

Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat

May 15, 2026

Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says - Moomoo

May 15, 2026

REGENXBIO Is Maintained at Overweight by Barclays - Moomoo

May 15, 2026

RGNX Maintained by Barclays -- Price Target Lowered to $12 - GuruFocus

May 15, 2026

A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $12 to $42 - Moomoo

May 15, 2026

Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $10 - Moomoo

May 15, 2026

Nasdaq Jumps Over 200 Points; Dillard's Shares Gain After Q1 Earnings - Sahm

May 15, 2026

Discipline and Rules-Based Execution in RGNX Response - Stock Traders Daily

May 15, 2026

Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $12 - Moomoo

May 15, 2026

REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval - Sahm

May 15, 2026

Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty - Investing.com

May 15, 2026

Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty By Investing.com - Investing.com Canada

May 15, 2026

Regenxbio posts mixed Phase III data on RGX-202 - The Pharma Letter

May 15, 2026